Culture Development Featured Articles
-
Gallus BioPharmaceuticals Utilises ambr15 Micro Bioreactor To Rapidly Optimise Process Development Of Novel Antibodies And Biosimilars
4/29/2014
TAP Biosystems, (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cellculture and fermentation systems for life science applications, is delighted to announce its ambr15 micro bioreactor system is being used at the leading US-based Contract Manufacturing Organisation (CMO), Gallus BioPharmaceuticals, LLC (“Gallus”) to optimise process development and clone selection of novel antibody therapeutics and biosimilars.
-
Irvine Scientific Announces Expansion Of BalanCD® Product Line To Serve Vaccine Market
4/14/2014
Irvine Scientific is pleased to announce the launch of its BalanCD® MDCK cell culture medium, a next generation cell culture product responding to today’s requirements for media used in cell-based vaccine manufacturing. This new flagship product expands Irvine Scientific’s current BalanCD product portfolio of animal component-free and chemically-defined media with the addition of a new purpose-built product.
-
Using Spray Drying For Flu Vaccines: What Challenges Do We Need To Overcome?
4/14/2014
When discussing the challenges of manufacturing flu vaccines, the conversation often shifts toward how manufacturers can meet the global demand each year. Currently there are some very innovative technologies aimed at addressing the challenge of manufacturing a larger supply of flu vaccines in a shorter amount of time, such as Novartis’ use of cell culture and Medicago and Fraunhofer’s use of tobacco plants. However, being able to deliver enough of a vaccine is only half the battle. It also needs to be delivered to its final destination within the appropriate temperature range. “It’s a huge misnomer for people who believe these technologies will unconstraint flu,” says Jim Robinson, VP of global technical operations, biological, and sterile products at Merck, who was involved in the manufacturing of billions of doses of flu vaccine prior to joining Merck. “The product still needs to get into a usable form and be delivered safely to the patient.”
-
Challenges In Generating And Optimizing A 3D Cell Culture Model
3/20/2014
Growing cells in a 3D culture is more preferable than a 2D culture on a plate or a support matrix because 3D culture allow the cells to grow with better cell-to-cell interaction and develop into a microtissue structure, which almost resembles the natural cellular environment.
-
Rentschler To Hold 3rd Industrial Cell Culture Tech Conference
3/18/2014
Rentschler Biotechnologie GmbH announced that it will hold the third Industrial Cell Culture Technology Conference this June in Laupheim, Germany.
-
3rd Industrial Cell Culture Technology Conference Announced By Rentschler
3/17/2014
Rentschler is pleased to announce the Laupheimer Zelltage: a conference to take place in Laupheim, Germany on June 2nd and 3rd, Germany hopes to offer a platform for sharing ideas, knowledge and expertise in the world of cell culture technology.
-
Where Do Ideas Come From? Create A Culture That Fosters Good Ideas
1/9/2014
We live in a fast-paced world driven by technology and competition, but in order to really stay ahead, we have to be able to slow down and think. We have to allow our minds the time to create good ideas. So how do we do this?
-
Hamilton Company Acquires Fogale's Biomass Measurement Business
12/9/2013
Hamilton concludes agreement to acquire the biotech sensors business of the French company Fogale Nanotech.
-
Noble Life Sciences Receives Grant To Develop Assays for Anti-Mestatic Drug Development
12/5/2013
Noble Life Sciences (Gaithersburg, MD) announced today that the company has been awarded a Technology Commercialization Fund (TCF) grant of $100,000 from the Maryland Technology Development Corporation (TEDCO). The grant will be used to develop assays to determine the effect of cancer treatments on metastatic cells derived directly from patients. Metastasis-initiating tumor cells isolated from the blood of cancer patients will be used to assay the activity of drugs both in culture and in novel metastatic mouse models developed using these invasive circulating tumor cells (CTCs).
-
Acquisition Expands Phase I Capabilities
12/3/2013
Clinical research firm PRA has announced it will be acquiring privately-held specialty research firm CRI Lifetree. CRI’s focus has been on early stage patient population studies with a focus in Human Abuse Liability (HAL), addiction, pain, psychiatry, neurology, pediatric and infectious disease services.
With three Clinical Pharmacology Centers and over 200 beds, combined with over 20 years of clinical experience, CRI is one of the largest providers of patient population Phase I and confined Phase II-III services in the United States.